Causes and Risk Factors for Death in Systemic Sclerosis: a Study from the EULAR Scleroderma Trials and Research (EUSTAR) Database
Overview
Authors
Affiliations
Objectives: To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods: Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria and prospectively followed in the EULAR Scleroderma Trials and Research (EUSTAR) cohort were analysed. EUSTAR centres completed a structured questionnaire on cause of death and comorbidities. Kaplan-Meier and Cox proportional hazards models were used to analyse survival in SSc subgroups and to identify predictors of mortality.
Results: Questionnaires were obtained on 234 of 284 fatalities. 55% of deaths were attributed directly to SSc and 41% to non-SSc causes; in 4% the cause of death was not assigned. Of the SSc-related deaths, 35% were attributed to pulmonary fibrosis, 26% to pulmonary arterial hypertension (PAH) and 26% to cardiac causes (mainly heart failure and arrhythmias). Among the non-SSc-related causes, infections (33%) and malignancies (31%) were followed by cardiovascular causes (29%). Of the non-SSc-related fatalities, 25% died of causes in which SSc-related complications may have participated (pneumonia, sepsis and gastrointestinal haemorrhage). Independent risk factors for mortality and their HR were: proteinuria (HR 3.34), the presence of PAH based on echocardiography (HR 2.02), pulmonary restriction (forced vital capacity below 80% of normal, HR 1.64), dyspnoea above New York Heart Association class II (HR 1.61), diffusing capacity of the lung (HR 1.20 per 10% decrease), patient age at onset of Raynaud's phenomenon (HR 1.30 per 10 years) and the modified Rodnan skin score (HR 1.20 per 10 score points).
Conclusion: Disease-related causes, in particular pulmonary fibrosis, PAH and cardiac causes, accounted for the majority of deaths in SSc.
Baas J, Varga J, Feghali-Bostwick C, Peters-Golden M, Fortier S bioRxiv. 2025; .
PMID: 40060695 PMC: 11888450. DOI: 10.1101/2025.02.26.640163.
Rotondo C, Busto G, Rella V, Barile R, Cacciapaglia F, Fornaro M Diagnostics (Basel). 2025; 15(4).
PMID: 40002639 PMC: 11854868. DOI: 10.3390/diagnostics15040488.
Hirose K, Kiriyama H, Minatsuki S, Nagae Y, Furusawa T, Hiruma T Int J Cardiol Heart Vasc. 2025; 57:101625.
PMID: 39990173 PMC: 11847537. DOI: 10.1016/j.ijcha.2025.101625.
Arrhythmia as a Possible Complication of Mycophenolate Mofetil in Systemic Sclerosis: A Case Report.
Moradi Z, Ardestani V, Tamartash Z, Karimi E, Kavosi H Case Rep Med. 2025; 2025:8858671.
PMID: 39975771 PMC: 11839254. DOI: 10.1155/carm/8858671.
Dorniak K, Gogulska Z, Viti A, Glinska A, Kulawiak-Galaska D, Fijalkowska J Diagnostics (Basel). 2025; 15(3).
PMID: 39941322 PMC: 11817609. DOI: 10.3390/diagnostics15030393.